Table 4 Demographic and clinical characteristics of the patients who maintained clinical remission or experienced a relapse of UC with IFX scheduled-maintenance treatment
Characteristics | Clinical remission with IFX maintenance (n = 7) | Relapse requiring IFX intensification (n = 17) | p value |
|---|---|---|---|
Sex (men/women), n (%) | 5 (71.4)/2 (28.6) | 11 (64.7)/6 (35.3) | 0.64 |
Age (years)* | 38.6 ± 20.7 | 43.1 ± 15.2 | 0.64 |
Disease duration (years)* | 7.2 ± 3.5 | 6.8 ± 4.3 | 0.68 |
Modified Truelove and Witts severity index* | 7.9 ± 3.6 | 10.3 ± 3.0 | 0.23 |
Mayo score (endoscopy)* | 3.0 ± 0.0 | 2.7 ± 0.5 | 0.02 |
Extent of disease | |||
Left-side type, n (%) | 2 (28.6) | 10 (58.8) | 0.17 |
Extensive colitis, n (%) | 5 (71.4) | 7 (41.2) | |
Concomitant medications | |||
Corticoteroids, n (%) | 0 (0.0) | 7 (41.2) | 0.04 |
Azathioprine/Mercaptopurine, n (%) | 4 (57.1) | 9 (52.9) | 0.85 |
Tacrolimus, n (%) | 3 (42.9) | 5 (29.4) | 0.53 |
Hemoglobin >9.8 g/dl at IFX initiation, n (%) | 5 (71.4) | 10 (58.8) | 0.56 |
Serum albumin >35 g/L at IFX initiation, n (%) | 2 (28.6) | 10 (58.8) | 0.18 |
Serum CRP <5 mg/L at 2 weeks after IFX initiation, n (%) | 6 (85.7) | 12 (70.6) | 0.44 |